The additional funding will support a Phase 2 clinical trial for an inhaled antisense oligonucleotide drug for people with cystic fibrosis who have the splicing mutation 3849+10Kb C-to-T.
Site Search
Showing 31 - 31 of 31 results
Press Release
|
April 3, 2024
|
3 min read